1-(4-AMINO-5-BROMO-6-(1 H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)-1 H-PYRAZOL-4-OL AND USE THEREOF IN THE TREATMENT OF CANCER

This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-...

Full description

Saved in:
Bibliographic Details
Main Authors CAMACHO GOMEZ, Juan Alberto, HOWARD, Danny Roland, Jr, CAMERON, John Scott, CASTRO-PALOMINO LARIA, Julio Cesar, BILIC, Sanela
Format Patent
LanguageEnglish
French
German
Published 21.07.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.
Bibliography:Application Number: EP20180707151